| |
Antibodies are a crucial reagent in R&D, diagnostics, & therapeutics. Download the eBook to learn how you can apply custom antibodies in your work. 
|
|
Today's Big NewsDec 12, 2022 |
| By Fraiser Kansteiner Sanofi may have backed down against Amgen in a recent M&A bidding war, but its initial offer that got the ball rolling on the $28 billion buyout of Horizon Therapeutics suggests the French Pharma has a desire for dealmaking. |
|
|
|
By Conor Hale,Andrea Park When we added up the salaries, stock options, vested shares and bonuses awarded across the industry, we found some interesting additions to our list of the biggest medtech bigwigs. |
By Heather Landi A federal appeals court ruled that the Biden administration cannot force religious healthcare providers to perform or pay for gender transition surgeries as it violates the religious rights of some Catholic organizations. |
By Zoey Becker After months of warnings from the company itself, Clovis Oncology has finally thrown in the towel. The company filed for chapter 11 bankruptcy protections and sold a pipeline candidate to Novartis. |
|
If the clinical supply chain is poorly managed, sponsors can struggle to cope with the complexities, causing issues. This playbook covers keys to identifying the need to implement an eClinical Supply Chain Management platform. Download now. 
|
|
By Max Bayer Janssen is unveiling additional phase 2 data of its new multiple myeloma bispecific antibody in patients looking for a life preserver after treatment failures. The data comes on the heels of the company formally asking U.S. regulators for approval last week. |
By Ben Adams Six pharma companies are on Santa’s naughty list this Christmas. AstraZeneca, Biogen, Daiichi Sankyo, Lundbeck, Novo Nordisk and UCB have all been hit by the U.K.’s drug marketing regulator the PMCPA. |
By Nick Paul Taylor Roche’s attempt to muscle in on paroxysmal nocturnal hemoglobinuria is on track. The subcutaneous anti-C5 recycling antibody crovalimab improved outcomes in a Chinese phase 3 trial, giving the Big Pharma a boost as it closes in on data from its showdown with AstraZeneca’s Soliris. |
By Kevin Dunleavy Roche’s leadership shuffle, which began in July, continued on Monday with the departure of pharma sector CEO Bill Anderson, who took over in 2019. But this year, the sector’s fortunes declined with several clinical setbacks. Anderson is leaving at the end of this year to “pursue other opportunities,” the company said in a release. |
By Conor Hale Acotec maintains a portfolio of drug-coated balloons and angioplasty hardware, all approved in China and backed by a local sales network. |
By Angus Liu Less than six months into the $1.9 billion acquisition of Sierra Oncology, GSK has started to explore the possibility of new indications for the deal centerpiece, JAK inhibitor momelotinib, Hesham Abdullah, GSK’s global head of oncology development, told Fierce Biotech at #ASH22. |
By Andrea Park The reverse merger’s 15 minutes of fame in medtech and biotech may have already timed out, but a trickle of SPAC deals have still come through this year. |
By Annie Burky CommonSpirit Health reported to HHS that a ransomware attack announced back in October compromised the protected health information of more than 623,700 people. |
By Andrea Park In its second safety alert this year, Smiths Medical has issued a letter to its customers detailing a pair of potential issues with the infusion sets used alongside its CADD line of infusion systems. |
By Paige Minemyer Blue Shield of California is teaming with DispatchHealth to roll out new in-home services as part of its broad Health Reimagined initiative. |
Fierce podcasts Don't miss an episode |
| This week on “The Top Line,” we discuss the latest from the Clinical Trials on Alzheimer’s Disease conference. Plus, we cover the week's news including an investigation into Neuralink, Google’s DeepMind and why things aren't working out for PI3Ks. |
|
|---|
|
|
|
Wednesday, January 25, 2023 | 11am ET / 8am PT This webinar, presented by AmerisourceBergen, will deliver insights to manufacturers and payers covering the need for education and best practices for increasing biosimilar adoption, current product landscape and upcoming product launches, and more. Register now. 
|
|
Video Revolutionize your monoclonal antibody (mAb) manufacturing with expert insights. Sponsored by: Gibco |
Whitepaper Learn how to develop a high-performing supply chain for GMP-manufactured chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific. Sponsored by: Thermo Fisher Scientific |
Whitepaper Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
Executive Summary Strategies to help scale-up for commercial manufacturing are critical to getting cell and gene therapies to patients as more advanced therapies reach late-stage clinical studies and regulatory decisions. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Research Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
Whitepaper Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| |
|
